Laser eye device maker Iridex's Q3 net loss narrows

Reuters

Nov 12, 2025

Laser eye device maker Iridex's Q3 net loss narrows

Overview

Iridex Q3 revenue grows 8% yr/yr, driven by glaucoma probe and Pascal system sales
Operating expenses decreased 12% yr/yr due to cost reduction measures
Net loss for Q3 narrows to $1.6 mln from $1.9 mln yr/yr

Outlook

Iridex expects to achieve cash flow breakeven in Q4 2025
Company aims for positive adjusted EBITDA for full year 2025
Iridex plans to sustain cash flow positivity going forward

Result Drivers

GLAUCOMA PROBE SALES - Revenue growth driven by increased sales of Cyclo G6 glaucoma probes
COST REDUCTION - Operating expenses decreased 12% due to cost-cutting measures
INVENTORY WRITE-DOWN - Gross margin impacted by a one-time inventory write-down

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue		$12.50 mln
Q3 EPS		-$0.09
Q3 Net Income		-$1.60 mln
Q3 Gross Profit		$4 mln
Q3 Operating Expenses		$5.40 mln

Press Release: ID:nGNX2WhwSC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2582397203"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582397203\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582397203?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582397203","market":"us","top_or_hot":-1,"title":"Laser eye device maker Iridex's Q3 net loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Laser eye device maker Iridex's Q3 net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Iridex Q3 revenue grows 8% yr/yr, driven by glaucoma probe and Pascal system sales</p></li><li><p>Operating expenses decreased 12% yr/yr due to cost reduction measures</p></li><li><p>Net loss for Q3 narrows to $1.6 mln from $1.9 mln yr/yr</p></li></ul><p><span>Outlook</span></p><ul><li><p>Iridex expects to achieve cash flow breakeven in Q4 2025</p></li><li><p>Company aims for positive adjusted EBITDA for full year 2025</p></li><li><p>Iridex plans to sustain cash flow positivity going forward</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>GLAUCOMA PROBE SALES - Revenue growth driven by increased sales of Cyclo G6 glaucoma probes</p></li><li><p>COST REDUCTION - Operating expenses decreased 12% due to cost-cutting measures</p></li><li><p>INVENTORY WRITE-DOWN - Gross margin impacted by a one-time inventory write-down</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$12.50 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.09</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.60 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Profit</p></td><td></td><td><p>$4 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$5.40 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX2WhwSC</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Laser eye device maker Iridex's Q3 net loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLaser eye device maker Iridex's Q3 net loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 05:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Laser eye device maker Iridex's Q3 net loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Iridex Q3 revenue grows 8% yr/yr, driven by glaucoma probe and Pascal system sales</p></li><li><p>Operating expenses decreased 12% yr/yr due to cost reduction measures</p></li><li><p>Net loss for Q3 narrows to $1.6 mln from $1.9 mln yr/yr</p></li></ul><p><span>Outlook</span></p><ul><li><p>Iridex expects to achieve cash flow breakeven in Q4 2025</p></li><li><p>Company aims for positive adjusted EBITDA for full year 2025</p></li><li><p>Iridex plans to sustain cash flow positivity going forward</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>GLAUCOMA PROBE SALES - Revenue growth driven by increased sales of Cyclo G6 glaucoma probes</p></li><li><p>COST REDUCTION - Operating expenses decreased 12% due to cost-cutting measures</p></li><li><p>INVENTORY WRITE-DOWN - Gross margin impacted by a one-time inventory write-down</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$12.50 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.09</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.60 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Profit</p></td><td></td><td><p>$4 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$5.40 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX2WhwSC</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRIX","symbol_name":"艾里德克斯","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nL1N3WN0ZC:1","article_id":"2582397203","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582397203","pubTimestamp":1762895639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Laser eye device maker Iridex's Q3 net loss narrowsOverviewIridex Q3 revenue grows 8% yr/yr, driven by glaucoma probe and Pascal system salesOperating expenses decreased 12% yr/yr due to cost reductio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRIX":"艾里德克斯","BK4082":"医疗保健设备"},"translate_title":"激光眼科设备制造商Iridex第三季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRIX":0.9},"content_text":"Laser eye device maker Iridex's Q3 net loss narrowsOverviewIridex Q3 revenue grows 8% yr/yr, driven by glaucoma probe and Pascal system salesOperating expenses decreased 12% yr/yr due to cost reduction measuresNet loss for Q3 narrows to $1.6 mln from $1.9 mln yr/yrOutlookIridex expects to achieve cash flow breakeven in Q4 2025Company aims for positive adjusted EBITDA for full year 2025Iridex plans to sustain cash flow positivity going forwardResult DriversGLAUCOMA PROBE SALES - Revenue growth driven by increased sales of Cyclo G6 glaucoma probesCOST REDUCTION - Operating expenses decreased 12% due to cost-cutting measuresINVENTORY WRITE-DOWN - Gross margin impacted by a one-time inventory write-downKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Revenue$12.50 mlnQ3 EPS-$0.09Q3 Net Income-$1.60 mlnQ3 Gross Profit$4 mlnQ3 Operating Expenses$5.40 mlnPress Release: ID:nGNX2WhwSCFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}